上海宣泰医药科技股份有限公司2025 年半年度报告 公司代码：688247 公司简称：宣泰医药 上海宣泰医药科技股份有限公司 上海宣泰医药科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司主营业务、核心竞争力不存在重大不利变化，持续经营能力不存在重大风险。公司已在 本报告"第三节管理层讨论与分析"-"四、风险因素"中详细披露了生产经营过程中可能面临的 各种风险，提请投资者查阅。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人郭明洁、主管会计工作负责人吴一鸣及会计机构负责人（会计主管人员）卫培 华声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经公司第二届董事会第十八次会议决议，公司 2025 年半年度拟以实施权益分派股权登记日登 记的总股本扣减公司回购专用证券账户中股份为基数分配利润，本次利润分配方案如下： 公司拟向全体股东每 10 ...

Group 1 - Kangfang Biotech's PD-1/CTLA-4 bispecific antibody KAITENI® has received approval for a new indication in the treatment of cervical cancer, marking the third indication for this drug [1] - Tianyi Medical has obtained product registration certificates for single-use continuous renal replacement therapy tubing and single-use hemodialysis tubing, both sterilized with ethylene oxide [2] - Jincheng Pharmaceutical's posaconazole enteric-coated tablets and injectable cefoperazone sodium have been approved, enhancing the company's competitiveness in the antifungal and anti-infection sectors [3] Group 2 - Prolo Pharma has received approval for the raw material drug succinate desvenlafaxine, expanding its product pipeline in the antidepressant treatment field [4] - Wantai Biological Pharmacy's first domestically produced nine-valent HPV vaccine has been approved, with approximately 1 billion yuan invested in research and development as of May 2025 [5] - Yuheng Pharmaceutical's subsidiary has signed a market promotion service agreement with Eisai (China) Pharmaceutical for the exclusive promotion of mecobalamin injection, which is used for peripheral neuropathy and vitamin B12 deficiency-related anemia [6]

Core Insights - The company Jin Cheng Pharmaceutical announced the receipt of drug registration certificates for its subsidiary's products, including Posaconazole enteric-coated tablets and injectable Cefoperazone sodium, enhancing its product portfolio in the antifungal and anti-infection sectors [1][2]. Group 1: Product Details - Posaconazole enteric-coated tablets are a second-generation triazole antifungal drug used for treating invasive aspergillosis and preventing infections caused by Aspergillus and Candida species, known for its broad antimicrobial spectrum, high activity, and good safety profile [1]. - Sales of Posaconazole enteric-coated tablets in China's public medical sector were reported as RMB 44.67 million, RMB 76.65 million, and RMB 201.33 million for the years 2021, 2022, and 2023, respectively [1]. - Injectable Cefoperazone sodium is indicated for treating infections caused by sensitive bacteria, including lower respiratory tract infections, urinary tract infections, and sepsis, and is sold in countries such as China, Japan, South Korea, Italy, and India [2]. Group 2: Market Position and Competitors - The main sales market for injectable Cefoperazone sodium is China, with reported sales of RMB 3.442 billion, RMB 4.257 billion, and RMB 4.494 billion for the years 2021, 2022, and 2023, respectively [2]. - Approved manufacturers for Posaconazole enteric-coated tablets in China include Qilu Pharmaceutical (Hainan) Co., Ltd. and Sichuan Kelun Pharmaceutical Co., Ltd. [1]. - Approved manufacturers for injectable Cefoperazone sodium include Chengdu Better Pharmaceutical Co., Ltd., Qilu Anti-Pharmaceutical Co., Ltd., and Harbin Pharmaceutical Group [2]. Group 3: Strategic Implications - The approval of Posaconazole enteric-coated tablets and injectable Cefoperazone sodium enriches the company's product line, which is expected to enhance its market competitiveness in the antifungal and anti-infection fields [2].

Group 1 - Company Jin Cheng Pharmaceutical (300233) announced that its subsidiary Beijing Jin Cheng Tai Er Pharmaceutical Co., Ltd. and its holding subsidiary Guangdong Jin Cheng Jin Su Pharmaceutical Co., Ltd. have received drug registration certificates from the National Medical Products Administration [1] - The drug Posaconazole enteric-coated tablets is a second-generation triazole antifungal medication used for the treatment of invasive aspergillosis and the prevention of invasive aspergillosis and candidiasis infections [1]

Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. reported significant growth in its 2024 annual results, with a revenue of 512 million yuan and a net profit of 128 million yuan, driven by strong sales and international market expansion [1][2]. Group 1: Financial Performance - In 2024, the company achieved an operating income of 512 million yuan, representing a year-on-year increase of 70.61% [1] - The net profit attributable to shareholders reached 128 million yuan, up 109.09% year-on-year, while the net profit after deducting non-recurring gains and losses was 114 million yuan, marking a 140.06% increase [1] - The company plans to distribute a cash dividend of 0.37 yuan per share, with a total dividend amounting to approximately 16.61 million yuan, which is over 50% of the net profit attributable to shareholders [1] Group 2: Sales Growth and Market Expansion - Product sales revenue for the year was 351 million yuan, a substantial increase of 99.64%, with revenue from equity participation reaching 46.82 million yuan, up 122.30% [2] - Key products such as Posaconazole enteric-coated tablets and Ursodeoxycholic acid capsules saw significant sales growth in the Chinese market, while Mesalazine enteric-coated tablets gained market share in the U.S. [2] - The company successfully commercialized several new products in China, including Sitagliptin Metformin extended-release tablets and Olaparib tablets, and expanded its international presence by signing multiple cooperation agreements in emerging markets [2] Group 3: Future Development Plans - In 2025, the company anticipates the completion of system certification for its complex formulation workshop, with the first complex injection project entering trial operations [3] - The company aims to enhance its R&D efforts in the injection field and develop new formulation platform technologies, transitioning from a generic drug company to a hybrid innovative pharmaceutical enterprise [3]